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Abstract
Background: Interactions between cancer cells and the surrounding microenvironment are crucial determinants of
cancer progression. During this process, bi-directional communication among tumor cells and cancer associated
fibroblasts (CAF) regulate extracellular matrix (ECM) deposition and remodeling. As a result of this dynamic process,
soluble ECM proteins can be released into the bloodstream and may represent novel circulating biomarkers useful
for cancer diagnosis. The aim of the present study was to measure the levels of three circulating ECM related
proteins (COL11A1, COL10A1 and SPARC) in plasma samples of lung cancer patients and in healthy heavy-smokers
controls and test whether such measurements have diagnostic or prognostic value.
Methods: Gene expression profiling of lung fibroblasts isolated from paired normal and cancer tissue of NSCLC
patients was performed by gene expression microarrays. The prioritization of the candidates for the study of
circulating proteins in plasma was based on the most differentially expressed genes in cancer associated fibroblasts.
Soluble ECM proteins were assessed by western blot in the conditioned medium of lung fibroblasts and by ELISA
assays in plasma samples.
Results: Plasma samples from lung cancer patients and healthy heavy-smokers controls were tested for levels of
COL11A1 and COL10A1 (n = 57 each) and SPARC (n = 90 each). Higher plasma levels of COL10A1 were detected in
patients (p ≤ 0.001), a difference that was driven specifically by females (p < 0.001). No difference in COL11A1 levels
between patients and controls was found. SPARC levels were also higher in plasma patients than controls (p < 0.
001) with good performance in discriminating the two groups (AUC = 0.744). No significant association was
observed between plasma proteins levels and clinicopathological features or survival.
Conclusion: Soluble factors related to proficient tumor-stroma cross-talk are detectable in plasma of primary lung
cancer patients and may represent a valuable complementary diagnostic tool to discriminate lung cancer patients
from healthy heavy-smokers individuals as shown for the SPARC protein.
Keywords: Lung cancer, Extracellular matrix (ECM), Circulating biomarkers, SPARC, Secreted protein acidic and rich
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Background
Lung cancer represents a major health issue worldwide
due to its high incidence and mortality rates [1]. The
disease is often diagnosed at advanced stages when
current clinical options are largely ineffective resulting
five years survival rates of less than 10% [2]. Identifica-
tion of circulating molecular biomarkers is therefore
critical to improve early detection of lung cancer and
represents an important approach with a large clinical
potential [3]. Despite the recent improvements in the
characterization of different circulating biomarkers such
as cell free DNA [4, 5], circulating tumor cells [6–8],
extracellular vesicles or circulating miRNA [9, 10], the
search for optimal biomarkers still remains a challenge.
In the past, most studies were centered on identifying
potential biomarkers using molecules differentially
expressed by tumor cells. However, in the last few years,
the concept that each tumor is a complex system com-
posed by both, cancer cells and the surrounding stroma,
represented by a variety of cell types such as fibroblasts,
immune and endothelial has been well established [11].
This notion has important implications for biomarkers
research as novel candidates with diagnostic or prognos-
tic value can potentially be obtained by analyzing mole-
cules produced by stromal cells during their interactions
with cancer cells [12, 13].
In particular, activated fibroblasts play a prominent role
in lung carcinogenesis due to their abilities to trigger
several signaling pathways implicated in tumor formation
and metastasis [14–16]. It has also been demonstrated
that cancer-associated fibroblasts (CAFs) within the react-
ive stroma are responsible for deposition of elevated
amounts of extracellular matrix (ECM) [17]. In physio-
logical condition, ECM provides mechanical and biochem-
ical support to the surrounding cells and is actively
involved in cell proliferation and migration [18]. On the
other hand, under pathological conditions the interactions
between activated fibroblasts and epithelial cells result in
production of different growth factors, cytokines and pro-
teases which modify the surrounding ECM, by changing
its composition and facilitating pathological alterations
such as chronic obstructive pulmonary disease (COPD) or
idiopathic pulmonary fibrosis (IPF) [19] and potentially
leading to cancer development [20, 21].
As a consequence of this remodeling, proteins related
to ECM are released into blood and could be considered
as potential novel circulating biomarkers [22]. Therefore,
new biomarkers for early detection of lung cancer
derived from remodeling of ECM could be developed by
identifying candidate genes and pathways from gene
expression profiling of cancer associated fibroblasts
(CAF). A recent review started to unravel the key path-
ways involved in their functional effects highlighting the
existence of common mechanisms as well as specificities
in different cancer types (breast, prostate and lung can-
cer) [23]. The results showed that most of the commonly
enriched gene sets characterizing tumor-promoting
fibroblasts were related to structural ECM molecules
and ECM organization (e.g. collagens) and in particular,
to the ECM3 signature, an ECM-based signature already
found associated with bad prognosis in aggressive breast
carcinomas (i.e. grade III) [24]. Mechanistically the
deposition of collagens in the surrounding tumor influ-
ences cancer cells behavior promoting cancer progres-
sion and invasion in several cancer types [25, 26].
However, the utility of any specific collagen fragment as
plasma circulating biomarker in lung cancer remains
unproven. Several studies have also pointed out the
importance of another lung microenvironment-related
protein, secreted protein acidic and rich in cysteine
(SPARC), a collagen-binding matricellular protein consid-
ered as a key player in the tumor progression most likely
by supporting crosstalk at the tumor–stroma interface
[27, 28]. SPARC has been predominantly detected in the
tumor-associated stroma, specifically in ECM produced by
activated fibroblasts. Interestingly, the localization of
SPARC in NSCLC tissues is linked to disease prognosis.
In fact, high levels of SPARC expression within NSCLC
tumor tissues, are associated to longer survival, while its
absence represents a negative prognostic factor. On the
other hand, high expression of SPARC in the stroma is as-
sociated with poor overall survival in lung cancer patients
[29]. Since changes in the ECM can occur early in cancer
progression, in this study we aimed to identify plasma cir-
culating proteins originated by the ECM compartment
and to investigate their potential utility as biomarkers for
early diagnosis of lung cancer. In addition, we aimed to
explore the association of ECM proteins with different
clinical parameters and their potential prognostic value.
Methods
Patient characteristics and tissue sampling
The current study was approved by the Fondazione IRCCS,
Istituto Nazionale dei Tumori Ethics Review Board and in-
cluded all consecutive patients from whom plasma samples
were available and who underwent a complete anatomical
resection for primary lung cancer at the Thoracic Surgery
Division of the National Cancer Institute of Milan, from
January 2012 to July 2014. Healthy heavy smoker controls
were enrolled in a lung cancer screening program (clinicalt
rial.gov NCT 02247453, www.biomild.org) from January
2013 to January 2016. Written informed consent was
obtained from all patients and healthy heavy smokers
controls for blood collection. All cases used in this study
were confirmed to be primary lung cancer by pathology re-
view. Study participants were mainly heavy smokers (12
non-smokers for the analysis of COL11A1 and COL10A1)
and were matched 1:1 to the patient cohorts according to
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sex and age classes (< 50, 50–54, 55–59, 60–64, 65–69,
70–75, > 75) for the analysis of COL11A1 and COL10A1
and according to sex, smoking history and age classes for
the analysis of SPARC. Overall survival was the study out-
come of interest, thus patients contributed with their time
interval from surgery until the date of death or until 16th
January 2017 for survivors. Blood collection was performed
shortly before surgery to avoid the impact of surgery in the
markers quantification. Plasma extraction was described
elsewhere [30]. Briefly, whole blood samples (5–10 ml)
were collected as first blood with spray-coated K2EDTA
tubes (BD-Becton, Dickinson and Company, Plymouth,
UK). Within 2 h, plasma was separated by a first centrifuga-
tion step at 2500 RPM at 4 °C for 10 min. The supernatant
containing plasma was carefully collected avoiding the frac-
tion closest to the lymphocytic ring. Plasma was then cen-
trifuged a second time at 2500 RPM at 4 °C for 10 min. and
the supernatant collected and stored at − 80 C until further.
Establishment of cell cultures and conditioned medium
Cultures of primary cancer-associated (CAF) and fibro-
blasts derived from normal counterpart of (NF) lung
cancer patients were isolated from surgical specimens
and cultured as already described [31]. All cell lines were
routinely tested to exclude presence of mycoplasma con-
tamination, grown as adherent monolayer and harvested
at controlled density. To obtain conditioned medium
(CM), cells were grown in controlled conditions in
serum free medium at the same density (cells number =
1X106). After 24 h, the CM was collected, centrifuged to
eliminate cell debris and stored at − 80 C until further.
RNA purification, microarray and data analysis
Total RNA was extracted from fibroblasts cell cultures
using RNA easy kit (Qiagen), followed by a clean-up
treatment to remove genomic DNA. RNA purity was
assessed with bioanalyzer (Agilent technologies) and
concentration of RNA was evaluated by nanodrop 2000c
(Thermo Scientific). Each microarray experiment was
performed using 300 ng of total RNA. Procedures
included first strand synthesis, second strand synthesis,
double-strand cDNA clean up, in vitro transcription,
cRNA purification and fragmentation. One microgram
of biotinylated cRNA were finally applied to each
hybridization array, Illumina Human HT-12v4 Expression
BeadChip (Illumina, Inc., San Diego, CA, USA) at 58 °C
for 18 h. Illumina BeadStudio software version 3.8 was
used to obtain the raw data. Class comparison analysis
was performed using the limma Bioconductor package
[32]. Cancer associated fibroblast were compared with
normal fibroblasts and all genes were ranked according to
the modified t-statistics values obtained. These ranked
gene lists were subjected to a Gene Set Enrichment
Analysis (GSEA, v.4.0) to identify Gene Ontology terms or
Canonical Pathways (BIOCARTA, KEGG, REACTOME)
significantly enriched. Enrichment was considered signifi-
cant at p-value < 0.05.
Cell lysates, extracellular matrix and conditioned medium
preparation
For cell lysates preparation, cell lines were solubilized
for 1 h on ice with TNTG lysis buffer containing 50 mM
Tris-HCl pH 7.5, 150 mM NaCl, 100 mM NaF, 10 mM
sodium pyrophosphate, 10% glycerol, 1% Triton X-100
and protease inhibitor cocktail (Complete Mini, Roche,
Basel, Switzerland). For extracellular matrix isolation,
cultured cells were treated with the hypotonic buffer
NH4OH 20 mM for 20 min. After two washes with
Phosphate-buffered saline (PBS) 1X the extracellular
matrix present on the plastic plate was recovered with
heated loading buffer (Laemmli solution) with the help
of a scraper. Protein levels in cell-derived extracellular
matrix were normalized with respect to the number of
cells seeded and grown in the same conditions of cells
used for extracellular matrix recovering. Conditioned
media (CMs) were processed with Amicon Ultra-15
Centrifugal Filter Unit with Ultracel-3 membrane (Merk
Millipore, Billerica, MA, USA) for concentration of pro-
teins with a molecular mass greater than 5 kDa, accord-
ing to the manufacturer’s instructions. Concentration
factors ranged from 30 to 40X.
Proteins analysis techniques
Western Blot. Protein lysates (20 μg), a fixed volume of
solubilized extracellular matrix (20 μl) or a fixed volume
of concentrated CM (26 μl) were mixed with loading
buffer under reducing conditions, heated for 5 min at
95 °C, loaded on 4–12% precast NuPage SDS-Bis-Tris
gels (Life Technologies, Carlsbad, CA, USA). The pro-
teins were then transferred to PVDF membranes (Merk
Millipore), stained with Red Ponceau to check loading
and membranes saturated for 1 h at room temperature in
blocking solution (5% low-fat milk in TBS + 0.1%
Tween-20) before probing with the appropriate anti-
bodies. Blots were washed with TBS-0.5% Tween-20 and
further incubated with horseradish peroxidase-conjugated
secondary antibodies (GE Healthcare, Little Chalfont, UK)
for 1 h at room temperature. Western blots were devel-
oped using the enhanced chemiluminescence method (GE
Healthcare) according to the manufacturer’s instructions.
Data were acquired and analyzed using Quantity One
4.6.6 software (Bio-Rad, Hercules, CA, USA). The follow-
ing primary antibodies were used: COL11A1 (1:500 rabbit
polyclonal, NBP1–55803, Novus Biologicals, Littleton, CO
USA), COL10A1 (1:1000 rabbit polyclonal, LS-C157654,
LSBio LifeSpan Biosciences, Seattle, WA USA), SPARC
(5 μg/ml mouse IgG1, 33–5500 Invitrogen), and vinculin
(1:1000 mouse monoclonal, hVIN-1 clone, Sigma Aldrich).
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Vinculin quantification, concentration factor and cell
counts were used to normalize ECM proteins in cell lysates,
CMs and extracellular matrix preparation, respectively.
Circulating proteins were measured by using commercially
available ELISA kits (COL10A1 and COL11A1 LifeSpan
Biosciences, Inc., SPARC R&D), according to manufacturer’s
instruction. Duplicate measures were performed for each
sample. Protein levels were expressed as OD value as
measured by Microplate Reader Tecan Infinite® M1000.
Statistical analysis
After matching, the analysis of the levels of ECM mole-
cules was performed on a set of 57 lung cancer patients
and 57 healthy controls for COL11A1 and COL10A1
and on a set of 90 lung cancer patients and 90 healthy
controls for SPARC. Raw absorbance values were cor-
rected by exploiting the values of the ELISA standards.
The distributions of the absorbance values of ECM mol-
ecules in plasma samples of lung cancer patients and
healthy controls were compared by using the Wilcoxon
test. The association between each molecule levels and
clinicopathological variables was investigated using the
Wilcoxon test for categorical variables and the Spearman
correlation coefficient for continuous variables. A uni-
variable logistic regression model including the molecule
was fitted for the comparison between patients and
healthy controls, and the area under the ROC curve
(AUC) was estimated as a measure of discriminative
ability Sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) correspond-
ing to the cutoff of the ROC maximizing the Youden
Index, were extrapolated. AUC, sensitivity/specificity,
PPV/NPV 95% confidence intervals were estimated
using bootstrap procedure (Efron B. An Introduction to
the Bootstrap. Chapman and Hall, New York, NY; 1993).
Multivariable quantile regression models with median as
the reference quantile were implemented to study the
association between the molecules and the disease status
(tumor vs control), adjusting for possible confounders
such as age, packyears, COPD and sex. Moreover, we
studied the prognostic effect of ECM molecule levels on
overall survival (OS). At univariable analyses each mol-
ecule was categorized according to its tertiles and the
Kaplan-Meier curves were estimated and statistically
compared by means of the log-rank test. Multivariable
Cox models were also implemented, where the effect of
the molecule was adjusted for age, packyears, COPD
(present vs absent) and sex (M vs F); the corresponding
Hazard Ratios (HR) were estimated. In all the models
the molecules were included as continuous variables
using 3-knots restricted cubic splines [33] The analyses
were carried out using R software, version 3.2.0 (http://
www.r-project.org/). The test results were considered
statistically significant whenever a two-sided p-value
below 0.05 was obtained.
Results
ECM-related gene expression profiles are enriched in lung
cancer associated fibroblasts
We reasoned that novel potential circulating biomarkers
derived from the tumor microenvironment could be
developed starting from the discovery of biological path-
ways defining activated stroma. To identify factors re-
sponsible for a proficient cross-talk between fibroblasts
and cancer cells in lung tumors, we have previously
characterized cancer-associated fibroblasts (CAF) and
normal fibroblasts (NF) isolated from patients with lung
cancer (n = 60) by gene expression profiles. Gene Set
Enrichment Analysis (GSEA) was used to identify groups
of genes whose expression was specifically altered in
cancer associated fibroblasts [23]. Class comparison ana-
lysis identified ECM deposition and remodeling among
the most enriched pathways in CAF as demonstrated by
the up-regulation of two important collagen isoforms,
COL11A1 and COL10A1. Interestingly these two pro-
teins also belong to a gene signature with prognostic
value so-called ECM3, originally derived by studying
expression changes of extracellular matrix genes in a co-
hort of breast cancer clinical specimens [24]. The ECM3
signature consists of 58 genes encoding 43 structural
ECM proteins we found that 11 out the 58 genes were
significantly differentially expressed between CAF and
NF, each contributing to an enrichment of the ECM3
signature in the activated fibroblasts phenotype (Table 1).
To understand the potential of ECM3-related genes as
circulating biomarkers, we have focused on three individ-
ual proteins, COL11A1 and COL10A1 that resulted the
most differentially expressed genes in CAF, and SPARC
which is also present in the ECM3 signature but not
significantly overexpressed in CAF. The prioritization of
these candidates was based on fibroblasts gene expression
profiling data for COL11A1 and COL10A1 and on the
existing literature on SPARC in lung tumorigenesis [27].
ECM-related proteins are enriched in CAF and selectively
released in conditioned medium
To validate the ECM-related genes expression patterns
at protein level we performed western blot analyses on
cell lysates of CAF (n = 3) and NF (n = 3) cell lines estab-
lished from lung cancer patients and found that
COL10A1 and SPARC were slightly enriched in CAF
compared to NF (p = 0.171 and p = 0.025 respectively),
while no differences in COL11A1 expression levels were
detected (p = 0.374) (Fig. 1a).
To evaluate whether fibroblasts could represent the
source of circulating ECM-related proteins and whether
these factors are preferentially released in the medium
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conditioned by CAF, we analyzed by western blot con-
ditioned medium obtained in serum-free conditions
from CAF and NF (n = 3, respectively). The analysis
revealed that CM by CAF was enriched in COL10A1
(p = 0.052) and SPARC (p = 0.004) as compared to NF,
while only a trend in the enrichment of COL11A1 protein
levels was found (p = 0.085) (Fig. 1b). We concluded that
fibroblasts represent one possible source of the secreted
proteins and that the differences in the release reflect their
expression levels in cell cultures total lysates. To exclude
protein deposition in a bound form in the extracellular
matrix we also analyzed protein expression in the decellu-
larized matrix without finding any of these proteins, thus
indicating their preferential release.
ECM-related proteins as lung cancer biomarkers
To demonstrate the potential clinical utility of ECM-re-
lated proteins as lung cancer circulating biomarkers, we
analyzed by ELISA assay matched plasma samples from
57 patients (TU) and 57 controls (CTR) for COL11A1
and COL10A1 and from 90 patients (TU) and 90 controls
(CTR) for SPARC. The matching was performed accord-
ing to clinical parameters (sex, age, smoke).
Main characteristics of the subjects included in the
present study are shown in Table 2. Overall, the results
showed that the levels of COL10A1 and SPARC were sig-
nificantly higher in lung cancer patients compared to
healthy controls (COL10A1: p = 0.001; SPARC: p < 0.001),
while no difference in the levels of COL11A1 could be de-
tected (p = 0.270) (Fig. 2). We further explored the levels
of the proteins in patients and controls stratifying by sex
(COL10A1 and COL11A1: M = 20, F = 37, SPARC: M =
62, F = 28 for both groups). Interestingly we found differ-
ent levels between patients and controls for COL10A1
Table 1 Modulation of ECM3 genes in CAF vs NF comparison
(microarray analysis)












































Table 1 Modulation of ECM3 genes in CAF vs NF comparison
(microarray analysis) (Continued)













Italic: Positive enrichment; Bold: Negative enrichment
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only in the female subgroup (p < 0.001) while no differ-
ences were found in males (p = 0.490) (Fig. 3a). The differ-
ence in SPARC levels between patients and controls
remained significant across gender subgroups (p <
0.001) (Fig. 3b) while there were no differences for
COL11A1 in gender subgroups (p = 0.232) in female
group and p = 0.134 in male group) (Fig. 3c). In multivari-
able quantile regression analysis, the COL11A1 protein
levels resulted as associated with disease status (p < 0.001),
while COL10A1 was no longer associated to the disease
status (p = 0.814) (Additional file 1: Table S1). No
significant association between OS and COL11A1
levels (p = 0.683) or COL10A1 levels (p = 0.960) was
found (Additional file 2: Figure S1). Accordingly, the two
variables resulted not significant at multivariable Cox
analysis (HR = 0.79 [0.25–2.52] p = 0.923 for COL11A1
and HR= 1.06 [0.26–4.35] for COL10A1 p = 0.300).
Reflecting the clinical scenario of resected NSCLC a
fraction of patients had received pre-operative chemother-
apy (14–16% of patients depending on cohorts, see Table
2). To verify whether chemotherapy (CT) treatment
affected circulating ECM molecule levels we considered
patients that were treated before surgery and we found
that the CT treatment was not associated with COL11A1
and COL10A1 levels (Fig. 4).
Circulating SPARC is an independent diagnostic factor
Based on the inconsistent results on COL11A1 and
COL10A1, we focused on SPARC protein. We performed
univariable and multivariable analyses to assess the
A
B
Fig. 1 ECM related molecules are increased in CAF and selectively released in their conditioned medium: a Western Blot analysis of whole lysates
of NF and CAF showing the protein levels of the three molecules (COL10A1, SPARC and COL11A1,) in CAF and NF cell cultures. The histograms
show relative quantification by densitometric analysis normalized to Vinculin. b Western Blot analysis for the presence of the proteins COL10A1,
SPARC and COL11A1 released in the CM of CAF or NF. The histograms show the densitometric analysis (in arbitrary Units) after normalization
with respect to total number of cells. The difference was considered significant at p-value < 0.05
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Healthy Controls (n = 57) Patients (n = 57) Healthy Controls (n = 90) Patients (n = 90)
Sex (%)
Male 20 (35%) 20 (35%) 62 (69%) 62 (69%)
Female 37 (65%) 37 (65%) 28 (31%) 28 (31%)
Age (mean,range) 66 (55–74) 65 (42–77) 66 (55–74) 66 (41–82)
Packyears (mean,range) 48 (20–112) 48 (4–158)
COPD (%)
Present 22 (39%) 16 (28%) 48 (53%) 38 (42%)
Absent 35 (61%) 39 (68%) 42 (47%) 50 (56%)
NA 2 (4%) 2 (2%)
COPD severity (%)
Severe 0 (0%) 0 (0%) 0 (0%) 2 (2%)
Moderate 5 (9%) 2 (3%) 4 (4%) 13 (14%)
Mild 17(30%) 14 (25%) 44 (49%) 23 (26%)
No 35 (61%) 39 (68%) 42 (47%) 50 (56%)
NA 2 (4%) 2 (2%)
Smoking history (%)
Current 40 (70%) 21 (37%) 66 (73%) 64 (71%)
Former 17 (30%) 24 (42%) 24 (27%) 26 (29%)
Never 0 (0%) 12 (21%)
Histology (%)
Adenocarcinoma 47 (82%) 54 (60%)




IA 18 (31%) 20 (22%)
IB 3 (5%) 12 (13%)
IIA 9 (16%) 9 (10%)
IIB 4 (7%) 3 (3%)
IIIA 17 (30%) 28 (31%)
IIIB 1 (2%) 5 (6%)
IV 5 (9%) 6 (7%)
NA 7 (8%)
CT treatment (%)
Yes 9 (16%) 13 (14%)
No 48 (84%) 77 (86%)
COL11A1 (median, IQR) 0.837 (0.653–1.043) 0.923 (0.759–1.172)
COL10A1 (median, IQR) 0.556 (0.471–0.647) 0.739 (0.640–0.882)
SPARC (median, IQR) 0.437 (0.343–0.555) 0.676 (0.501–0.956)
Andriani et al. BMC Cancer  (2018) 18:899 Page 7 of 14
association between plasma SPARC levels and other estab-
lished clinicopathological parameters such as age, smoking
(in terms of packyears), tumor stage and COPD.
As already assessed SPARC was significantly strongly
elevated in lung cancer patients compared to healthy
controls (p < 0.001) and remained significant across
gender subgroups (p < 0.001). In univariable analysis, no
association between SPARC protein levels and any of the
clinicopathological characteristic was detected. No signifi-
cant difference in SPARC levels was detected among
tumor stages (p = 0.916), suggesting that circulating
SPARC levels could represent a potential valuable
biomarker in early stage lung cancer (Fig. 5a). Also, the
correlation between SPARC levels and packyears resulted
as not statistically significant (p = 0.154, Fig. 5b). In multi-
variable analysis, the protein levels were associated with
disease status, even after adjustment for age, packyears,
COPD and sex (p ≤ 0.001) (Table 3). Therefore, in both
univariable and multivariable analyses, SPARC levels
resulted higher in the presence of lung cancer. This is also
mirrored by the ROC curve where circulating SPARC
levels showed a good capability to discriminate patients
from controls (AUC= 0.744, Fig. 6a). The optimal cutoff
maximizing the Youden Index of the ROC for SPARC was
0.587 (corrected - OD values) corresponding to a sensitivity
of 64.4% [54.4–74.4%] and specificity of 78.9% [70.0–87.8%]
(Additional file 3: Table S3), and to a PPV of 73.7%
[64.8–83.3%] and a NPV of 72.5% [65.1–83.1%]. There-
fore, if SPARC is over the optimal cutoff, the probabil-
ity of a true positive finding is 73.7%, while for values
below the optimal cutoff the probability of a true nega-
tive is 72.5%.
Concerning SPARC prognostic value, we did not find
any association between OS and SPARC levels in tertiles
both in the entire case series (p = 0.990) or considering
early stage patients only (p = 0.461) (Fig. 6b, c). Also using
the optimal cutoff for SPARC there was not any significant
association (p = 0.971). Moreover, the molecule levels
resulted not significant at multivariable Cox analysis, i.e.
HR = 1.06 [0.57–1.99] (p = 0.593). Interestingly, SPARC
levels were significantly lower for pre-treated patients
(p = 0.037), indicating that SPARC levels could be an
indicator of treatment response (Fig. 4).
Discussion
In this study, we aimed to determine whether proteins
related to the extracellular matrix are released in plasma
and can potentially be useful as lung cancer biomarkers.
We started our investigation from gene expression pro-
filing of lung fibroblasts which are known to play an im-
portant role in cancer progression and ECM remodeling
[20]. This approach revealed that ECM related proteins
are particularly enriched in primary cultures of CAF
from lung cancer patients [23] and also released in their
conditioned culture medium. We then focused on mole-
cules belonging to the ECM3 signature, previously iden-
tified in breast cancer and found to be prognostic when
overexpressed in the most aggressive tumors [24]. We
therefore analyzed two isoforms of collagens (COL11A1
and COL10A1 as the most expressed in lung fibroblasts
gene profiling) and SPARC. Collagens represents the most
abundant proteins of extracellular matrix and recent stud-
ies have highlighted an important role for COL11A1 and
COL10A1 in many aspects of neoplastic progression [34].
Previous observations reported that COL11A1 is more
expressed in CAF than in normal breast or pancreatic
fibroblasts [35–37]. Overexpression of COL11A1 was also
found in non-small cell lung cancer tissue samples where
it correlates with pathological stage, presence of lymph
node metastasis, and poor prognosis [36, 38]. Our study
showed higher COL11A1 gene expression in CAF com-
pared to NF, but no difference in protein expression in
Fig. 2 Levels of COL10A1 and SPARC are significantly higher in plasma of lung cancer patients compared to healthy heavy controls. a and c Box
plots of COL10A1 and COL11A1 levels measured in plasma of 57 lung cancer patients (TU) and 57 healthy donors (CTR). b Boxplots of SPARC
levels measured in plasma of 90 lung cancer patients (TU) and 90 controls (CTR), p =Wilcoxon test p-value
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cells or its release in culture medium. In addition, we did
not find any difference in protein levels in plasma of
patient’s vs heavy-smokers controls highlighting the
inadequacy of this protein as potential indicator of patho-
logical features. This observation indicates that COL11A1
is albeit differentially expressed in CAF is not sufficiently
discriminatory at the protein level.
Instead, COL10A expression showed remarkable signifi-
cant difference between controls and lung cancer patients
thus constituting a potential diagnostic candidate. However,
subgroup analyses showed that this finding was restricted
to the female group. In recent years, the importance of gen-
der related biomarkers has gained more attention especially
for lung cancer [39]. Several biological processes showed
substantial differences between males and females in vari-
ous hormonal states highlighting their impact on biomarker
studies [40]. In this work even if we do not have additional
data or insights to potentially explain such differences we
underline that gender effects should be considered before
starting any biomarkers development study. Our data sug-
gest however that COL10A1 could represent a potentially
promising biomarker for lung cancer in females and that its
relevance could be potentially explored in gender-related
cancers such as breast or ovarian or in specific subgroups
in other cancers. The most promising results were obtained
from the study on SPARC protein. Although SPARC has
recently emerged as a prognostic biomarker in different tu-
mors [41–43], its role in lung cancer remains controversial
[44]. In non-small cell lung cancer, the localization (stromal
or tumoral) of SPARC expression is associated with differ-
ent disease prognosis. Absence of SPARC expression within
the tumors is a negative prognostic factor [42] while high
Fig. 3 Circulating COL10A1 levels are preferentially increased in female lung cancer patients. Box plots showing levels of proteins in female and
male groups of controls and patients separately (a = COL10A1, b = SPARC, c = COL11A1), p =Wilcoxon test p-value
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levels of SPARC protein expression, albeit rare, are associ-
ated with longer survival and could be protective against
tumor aggressiveness [45]. On the other hand, patients
bearing SPARC-positive stroma have significantly poorer
overall survival [29]. Other studies found no prognostic im-
pact of stromal SPARC expression [46]. To our knowledge,
this is the first study showing the release of high levels of
SPARC in plasma of lung cancer patients to indicate that
this protein could represent a useful diagnostic biomarker
for lung cancer. Based on the previous literature and given
the detectable levels of SPARC in conditioned medium of
fibroblasts, we can hypothesize that the source of circulat-
ing SPARC in our patients is from stromal fibroblasts,
rather than from cancer cells, and that protein levels in
plasma could reflect changes in a microenvironment that
becomes activated and permissive to tumor growth and
progression.
SPARC protein levels in plasma were high in all stages
of the disease indicating that this could also serve as
marker of early lung cancer. Consistently with a previous
study [46] we did not find any association between levels
of circulating SPARC and the prognosis of our patients,
reinforcing the hypothesis that its presence reflects early
changes in the microenvironment more related with
initial tumor growth than relapse and metastasis. There-
fore, we can speculate that SPARC expression could influ-
ence stroma responsiveness during tumor formation,
representing an indicator of the disease at its earlier phases.
The effect of SPARC on malignant progression may instead
depend on other events such as EMT, growth factor or
immune modulation [47, 48].
Most importantly, the multivariate analysis also con-
firmed the significant association between disease status
and levels of circulating SPARC. Interestingly, the obser-
vation that SPARC could be a promising diagnostic
biomarker was confirmed by the ROC analysis, showing
an AUC of 0.744, with an optimal cutoff corresponding to
64.4% of sensitivity and 78.9% of specificity. However
further studies involving larger numbers of subjects are
required to confirm these results.
Interestingly, it has been suggested that ECM modifica-
tion provides protection against chemotherapy-induced
Fig. 4 Circulating SPARC levels decrease in CT pretreated-lung cancer patients. Box plots showing ECM molecule (COL10A1, SPARC, COL11A1)
levels after treatment with chemotherapy before surgery. p =Wilcoxon test p-value
Fig. 5 SPARC levels are not associated to tumor stage or smoking history (packyears). a Box plots showing SPARC levels in different tumor stages
(I-II vs III-IV), p =Wilcoxon test p-value. b Correlation between SPARC levels and lifetime smoke exposure (packyears), p = Spearman
correlation p-value
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apoptosis and may play a role in the failure of cancer ther-
apy [49]. Since the decrease (in terms of degradation) of
ECM related proteins could be a marker of drug response
we analyzed in this study patients that were treated with
chemotherapy before surgery. Although our results are
preliminary due to the low number of cases analyzed we
report slightly decreased levels of SPARC protein in these
patients indicating that beside a diagnostic marker SPARC
may represent a marker of treatment response. Future
longitudinal studies are however needed before firm
conclusions can be drawn.
In conclusion, this is the first study to test circulating bio-
markers related to ECM remodeling as possible diagnostic
tools for lung cancer patients. SPARC emerged as the most
promising biomarker, but it is possible that other genes
identified in the comparative expression analysis of lung
fibroblasts could be also useful for diagnostic purpose,
Table 3 quantile regression multivariable analysis of association
between SPARC levels and the characteristics of 90 lung cancer





Age (72 vs 62a) 0.002 [−0.003; 0.007] 0.563
Packyears (59 vs 33a) 0.001 [−0.001; 0.004] 0.647
COPD (Yes vs No) −0.015 [−0.057; 0.055] 0.748
Sex (M vs F) −0.046 [− 0.127; 0.035] 0.412
Disease status (Tumor vs Control) 0.255 [0.178; 0.285] < 0.001
athe two values are, respectively, the 3rd and 1st quartile of the
variable distribution
Fig. 6 Circulating SPARC evaluation as a diagnostic and prognostic marker. a ROC curve of SPARC evaluating the capability of SPARC levels to
discriminate between lung cancer patients and controls, with AUC and its bootstrap 95% CI. The optimal cutoff and sensitivity and specificity
corresponding to the optimal cutoff of the ROC are reported. b Kaplan Meier overall survival (OS) curves for SPARC levels divided into three
categories (≤1st tertile, 1st-2nd tertile, >2nd tertile) on the entire case series. c Kaplan Meier OS curves for SPARC levels divided into three
categories (≤1st tertile, 1st-2nd tertile, >2nd tertile) on stage I-II patients, p = log-rank test p-value
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either alone or in combination. It is now apparent, in fact,
that panels of protein-based and nucleic acids-based cancer
biomarkers, as opposed to single biomarkers, will probably
be necessary for reliable cancer detection, especially to im-
prove selection of high-risk individuals for CT screening
and to distinguish malignant from benign nodules or iden-
tify patients with particularly aggressive cancers. Since the
classical ELISA method that we used in our study suffer
limitations in analysis time, sample size, equipment cost,
and is not easily scalable to measure panels of proteins,
new bioanalytical technologies should be developed to
realize the full potential of protein biomarkers in the
clinical setting. Our work represents an explorative study to
verify whether proteins derived from ECM could be mea-
sured in plasma of lung cancer patients and their utility as
circulating biomarkers and provides proof-of-concept on
the feasibility and potential of this approach. Additionally,
our study supports the concept that stroma-related plasma
biomarkers may better fit as early diagnostic biomarkers
than those strictly tumor-related. However, large prospect-
ive clinical studies are clearly warranted to confirm our
preliminary results and further explore the existing poten-
tial of ECM-related circulating proteins.
Conclusions
In conclusion, we show here that circulating extracellu-
lar matrix related protein could be used as potential
biomarkers for early diagnosis of lung cancer. In particu-
lar, SPARC emerged as the most promising biomarker
representing an indicator of the disease at its earlier
phases. Interestingly also COL10A expression showed
remarkable significant difference between controls and
lung cancer patients thus constituting a potential diag-
nostic candidate. However, subgroup analyses showed
that this finding was restricted to the female group.
Our study also highlighted the inadequacy of COL11A1
protein as potential indicator of pathological features.
Taken together, our findings sustain the hypothesis that
stroma-related plasma biomarkers could represent
promising early diagnostic biomarkers related to inter-
actions between incipient tumors and the surrounding
microenvironment.
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